Plain-English translation of NCT07064577 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Radiation therapy for head and neck cancer often causes painful skin damage called radiation dermatitis. This trial is testing a new treatment called , which is designed to prevent or reduce this skin damage. Researchers want to see if this medication can help protect your skin during cancer treatment.
Radiation dermatitis is a very common side effect that can be severe enough to interrupt or delay cancer treatment, and currently there is no standard way to prevent it. This trial exists to test whether this new treatment could offer patients a better option.
You likely qualify if…
You likely don't qualify if…
If you are selected for this trial, you would receive the new nanoenzyme treatment alongside your regular radiation therapy for head and neck cancer. The study will compare how your skin responds compared to standard care. You would likely visit the hospital regularly for your cancer treatment and skin monitoring, with the research team tracking how well the treatment works at preventing skin damage.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Sponsor
West China Hospital
Enrollment target
~30 participants
Started
July 2025
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xingchen Peng, Prof.
Sichuan University West China Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.